The Effect of Upadacitinib on Bone Erosion in Patients with RA

One patient developed a chest infection, which required hospitalization, and withdrew from the study. No other serious adverse events were noted.

In Summary

The study results suggest upadacitinib can be clinically useful in patients with refractory RA, and that it may delay the progression of bone erosion. Additionally, bone erosion regression with upadacitinib may be more likely to occur in patients with RA who have had limited exposure to conventional synthetic DMARDs. Whether early JAK1 inhibition may lead to better structural outcomes warrants further investigation in a more controlled setting.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Highlights of prescribing information: Rinvoq (upadacitinib). U.S. Food & Drug Administration. 2023 Apr 10.
Ho So, Cheng I, Hung V, Tam L. Effect of upadacitinib on bone erosion repair in rheumatoid arthritis: A pilot study [abstract: 0305]. Arthritis Rheumatol. 2022 Oct;74(suppl 9).

The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) based on a short-term study that demonstrated improved pain, function and other symptoms of nr-axSpA in patients with active disease.

A post-hoc analysis showed upadacitinib is safe and effective for treating RA patients when used with methotrexate or non-methotrexate csDMARDs…

As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…

Based on data from two phase 3 clinical trials, Health Canada has approved the use of upadacitinib to treat adults with active psoriatic arthritis.

In Summary

References

FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis

Upadacitinib + Methotrexate & Other csDMARDs in RA Patients

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

Health Canada Approves Upadacitinib to Treat Adults with PsA

In Summary

References

Related Articles